Liver Cancer Medications

*generic version available
E experimental

Chemotherapy Medications

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td>Multiple</td>
<td>Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, <a href="#">click here</a>.</td>
</tr>
</tbody>
</table>

Immunotherapy Medications

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda</td>
<td>pembrolizumab</td>
<td>Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Opdivo</td>
<td>nivolumab</td>
<td>Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.</td>
</tr>
<tr>
<td>Tecentriq</td>
<td>atezolizumab</td>
<td>Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma.</td>
</tr>
</tbody>
</table>

**Targeted Therapy Medications** Learn more >>  More >>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GENERIC NAME</th>
<th>DRUG INDICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avastin</td>
<td>bevacizumab</td>
<td>Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.</td>
</tr>
<tr>
<td>Cabometyx</td>
<td>cabozantinib</td>
<td>Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).</td>
</tr>
<tr>
<td>Cyramza</td>
<td>ramucirumab</td>
<td>Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.</td>
</tr>
<tr>
<td>DRUG</td>
<td>GENERIC NAME</td>
<td>DRUG INDICATION</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lenvima</td>
<td>lenvatinib</td>
<td>Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.</td>
</tr>
<tr>
<td>Nexavar</td>
<td>sorafenib</td>
<td>Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.</td>
</tr>
<tr>
<td>Rozlytrek</td>
<td>entrectinib</td>
<td>Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.</td>
</tr>
<tr>
<td>Stivarga</td>
<td>regorafenib</td>
<td>Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).</td>
</tr>
<tr>
<td>Vitrakvi</td>
<td>larotrectinib</td>
<td>Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.</td>
</tr>
</tbody>
</table>

**DRUG** Chemotherapy  
**GENERIC NAME** Multiple  
**DRUG INDICATION**  
Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, [click here](#).

**DRUG** Keytruda  
**GENERIC NAME** pembrolizumab  
**DRUG INDICATION**  
Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, relapsed or refractory classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden.

**DRUG** Opdivo  
**GENERIC NAME** nivolumab
DRUG Opdivo
DRUG INDICATION
Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, metastatic small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, recurrent or metastatic esophageal cancer and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations.

DRUG Tecentriq
GENERIC NAME atezolizumab
DRUG INDICATION
Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, triple-negative breast cancer, metastatic liver cancer and inoperable or metastatic melanoma.

DRUG Avastin
GENERIC NAME bevacizumab
DRUG INDICATION
Avastin is a VEGF inhibitor approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic kidney cancer (renal cell carcinoma), recurrent or metastatic cervical cancer, recurrent glioblastoma brain cancer, liver cancer, and ovarian, fallopian tube or primary peritoneal cancer. Mvasi and Zirabev are biosimilar medications.

DRUG Cabometyx
GENERIC NAME cabozantinib
DRUG INDICATION
Cabometyx is a multikinase inhibitor approved for advanced kidney cancer (renal cell carcinoma) and previously treated liver cancer (hepatocellular carcinoma).

DRUG Cyramza
GENERIC NAME ramucirumab
DRUG INDICATION
Cyramza is a VEGFR2 inhibitor approved for treatment of cancer of the stomach or gastroesophageal junction (where the stomach meets the esophagus), metastatic non-small-cell lung cancer, metastatic colorectal cancer and inoperable or metastatic liver cancer.

DRUG Lenvima
GENERIC NAME lenvatinib
DRUG INDICATION
Lenvima is a multikinase inhibitor approved for treatment of recurrent or metastatic thyroid cancer, previously treated kidney cancer and inoperable liver cancer.

DRUG Nexavar
GENERIC NAME sorafenib
**DRUG** Nexavar
**DRUG INDICATION**
Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

**DRUG** Rozlytrek
**GENERIC NAME** entrectinib
**DRUG INDICATION**
Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

**DRUG** Stivarga
**GENERIC NAME** regorafenib
**DRUG INDICATION**
Stivarga is a multikinase inhibitor approved for metastatic colorectal cancer, advanced or metastatic gastrointestinal stromal tumor (GIST) and liver cancer previously treated with Nexavar (sorafenib).

**DRUG** Vitrakvi
**GENERIC NAME** larotrectinib
**DRUG INDICATION**
Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.

© 2020 Smart + Strong All Rights Reserved.
https://www.cancerhealth.com/drug_charts/liver-cancer-medications-drugs